Martijn V Verhagen1,2, Leon J Menezes3,4, Deena Neriman3, Tom A Watson2, Shonit Punwani1, Stuart A Taylor1,5, Ananth Shankar5,6, Stephen Daw6, Paul D Humphries7,2. 1. Department of Radiology, University College London Hospital, London, United Kingdom. 2. Department of Radiology, Great Ormond Street Hospital, London, United Kingdom. 3. UCL Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom. 4. NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom. 5. Centre for Medical Imaging, CBH, London, United Kingdom; and. 6. Department of Pediatrics, University College London Hospital, London, United Kingdom. 7. Department of Radiology, University College London Hospital, London, United Kingdom; paul.humphries5@nhs.net.
Abstract
Treatment regimens for pediatric Hodgkin lymphoma (HL) depend on accurate staging and treatment response assessment, based on accurate disease distribution and metabolic activity depiction. With the aim of radiation dose reduction, we compared the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment. Methods: Twenty-four patients (mean age, 15.4 y; range, 8-19.5 y) with histologically proven HL were prospectively and consecutively recruited in 2015 and 2016, undergoing both 18F-FDG PET/CT and 18F-FDG PET/MRI at initial staging (n = 24) and at response assessment (n = 21). The diagnostic accuracy of 18F-FDG PET/MRI for both nodal and extranodal disease was compared with that of 18F-FDG PET/CT, which was considered the reference standard. Discrepancies were retrospectively classified as perceptual or technical errors, and 18F-FDG PET/MRI and 18F-FDG PET/CT were corrected by removing perceptual error. Agreement with Ann Arbor staging and Deauville grading was also assessed. Results: For nodal and extranodal sites combined, corrected staging 18F-FDG PET/MRI sensitivity was 100% (95% CI, 96.7%-100%) and specificity was 99.5% (95% CI, 98.3%-99.9%). Corrected response-assessment 18F-FDG PET/MRI sensitivity was 83.3% (95% CI, 36.5%-99.1%) and specificity was 100% (95% CI, 99.2%-100%). Modified Ann Arbor staging agreement between 18F-FDG PET/CT and 18F-FDG PET/MRI was perfect (κ = 1.0, P = 0.000). Deauville grading agreement between 18F-FDG PET/MRI and 18F-FDG PET/CT was excellent (κ = 0.835, P = 0.000). Conclusion: 18F-FDG PET/MRI is a promising alternative to 18F-FDG PET/CT for staging and response assessment in children with HL.
Treatment regimens for pediatric Hodgkin lymphoma (HL) depend on accurate staging and treatment response assessment, based on accurate disease distribution and metabolic activity depiction. With the aim of radiation dose reduction, we compared the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment. Methods: Twenty-four patients (mean age, 15.4 y; range, 8-19.5 y) with histologically proven HL were prospectively and consecutively recruited in 2015 and 2016, undergoing both 18F-FDG PET/CT and 18F-FDG PET/MRI at initial staging (n = 24) and at response assessment (n = 21). The diagnostic accuracy of 18F-FDG PET/MRI for both nodal and extranodal disease was compared with that of 18F-FDG PET/CT, which was considered the reference standard. Discrepancies were retrospectively classified as perceptual or technical errors, and 18F-FDG PET/MRI and 18F-FDG PET/CT were corrected by removing perceptual error. Agreement with Ann Arbor staging and Deauville grading was also assessed. Results: For nodal and extranodal sites combined, corrected staging 18F-FDG PET/MRI sensitivity was 100% (95% CI, 96.7%-100%) and specificity was 99.5% (95% CI, 98.3%-99.9%). Corrected response-assessment 18F-FDG PET/MRI sensitivity was 83.3% (95% CI, 36.5%-99.1%) and specificity was 100% (95% CI, 99.2%-100%). Modified Ann Arbor staging agreement between 18F-FDG PET/CT and 18F-FDG PET/MRI was perfect (κ = 1.0, P = 0.000). Deauville grading agreement between 18F-FDG PET/MRI and 18F-FDG PET/CT was excellent (κ = 0.835, P = 0.000). Conclusion: 18F-FDG PET/MRI is a promising alternative to 18F-FDG PET/CT for staging and response assessment in children with HL.
Authors: H J A Adams; T C Kwee; B de Keizer; R Fijnheer; J M H de Klerk; A S Littooij; R A J Nievelstein Journal: Ann Oncol Date: 2013-12-18 Impact factor: 32.976
Authors: Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-01-31 Impact factor: 508.702
Authors: Marilyn J Goske; Kimberly E Applegate; Dorothy Bulas; Priscilla F Butler; Michael J Callahan; Brian D Coley; Steven Don; Donald P Frush; Marta Hernanz-Schulman; Sue C Kaste; Gregory Morrison; Manrita Sidhu; Keith J Strauss; S Ted Treves Journal: Pediatr Radiol Date: 2011-08-17
Authors: Shonit Punwani; Stuart A Taylor; Alan Bainbridge; Vineet Prakash; Steven Bandula; Enrico De Vita; Oystein E Olsen; Sharon F Hain; Nicola Stevens; Stephen Daw; Ananth Shankar; Jamshed B Bomanji; Paul D Humphries Journal: Radiology Date: 2010-04 Impact factor: 11.105
Authors: Margit Kleis; Heike Daldrup-Link; Katherine Matthay; Robert Goldsby; Ying Lu; Tibor Schuster; Carole Schreck; Philip W Chu; Randall A Hawkins; Benjamin L Franc Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-22 Impact factor: 9.236
Authors: Arash Latifoltojar; Shonit Punwani; Andre Lopes; Paul D Humphries; Maria Klusmann; Leon Jonathan Menezes; Stephen Daw; Ananth Shankar; Deena Neriman; Heather Fitzke; Laura Clifton-Hadley; Paul Smith; Stuart A Taylor Journal: Eur Radiol Date: 2018-06-15 Impact factor: 5.315